Abstract
INTRODUCTION
Alzheimer’s disease (AD) is a neurodegenerative disorder with multifactorial etiology, including genetic factors that play a significant role in disease risk and resilience. However, the role of genetic diversity in preclinical AD studies has received limited attention.
METHODS
We crossed five Collaborative Cross strains with 5xFAD C57BL/6J female mice to generate F1 mice with and without the 5xFAD transgene. Amyloid plaque pathology, microglial and astrocytic responses, neurofilament light chain levels, and gene expression were assessed at various ages.
RESULTS
Genetic diversity significantly impacts AD-related pathology. Hybrid strains showed resistance to amyloid plaque formation and neuronal damage. Transcriptome diversity was maintained across ages and sexes, with observable strain-specific variations in AD-related phenotypes. Comparative gene expression analysis indicated correlations between mouse strains and human AD.
DISCUSSION
Increasing genetic diversity promotes resilience to AD-related pathogenesis, relative to an inbred C57BL/6J background, reinforcing the importance of genetic diversity in uncovering resilience in the development of AD.
Highlights
Genetic diversity’s impact on AD in mice was explored.
Diverse F1 mouse strains were used for AD study, via the Collaborative Cross.
Strain-specific variations in AD pathology, glia, and transcription were found.
Strains resilient to plaque formation and plasma neurofilament light chain (NfL) increases were identified.
Correlations with human AD transcriptomics were observed.
If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.
This post is Copyright: Neelakshi Soni,
Lindsay A. Hohsfield,
Kristine M. Tran,
Shimako Kawauchi,
Amber Walker,
Dominic Javonillo,
Jimmy Phan,
Dina Matheos,
Celia Da Cunha,
Asli Uyar,
Giedre Milinkeviciute,
Angela Gomez‐Arboledas,
Katelynn Tran,
Catherine C. Kaczorowski,
Marcelo A. Wood,
Andrea J. Tenner,
Frank M. LaFerla,
Gregory W. Carter,
Ali Mortazavi,
Vivek Swarup,
Grant R. MacGregor,
Kim N. Green | March 1, 2024